美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

AI醫療

544.34

-1.8563-0.34%

漲家數：2

跌家數：2

平家數：- -

市盈率：- -

高：563.39

開：544.60

低：537.28

收：546.20

成交量：1,819.24萬

成交額：3.85億

市值：167.22億

流通市值：123.66億

資料載入中...

總覽新聞資訊

Tempus與第一三共達成戰略合作推進AI驅動的生物標誌物發現與ADC臨床項目差異化

BUZZ-與第一三共合作開發抗癌藥物，Tempus AI 股價上漲

Recursion Pharmaceuticals任命Vicki Goodman為首席醫療官，2026年4月6日生效

BUZZ-基因編輯藥物有望治療罕見肺病和肝病，Beam Therapeutics公司股價上漲

Beam Therapeutics股價盤前飆升14%，基因編輯藥物在罕見肺肝疾病試驗中展現積極成果

Beam Therapeutics公司：60毫克劑量被確定為最佳生物劑量，單劑量隊列展現優異安全性與療效

Beam Therapeutics公布BEAM-302治療α-1抗胰蛋白酶缺乏症1/2期試驗最新積極數據支持推進關鍵性開發階段

Beam Therapeutics：經BEAM-302 60毫克治療後，校正型M-AAT佔總AAT的94%，同時突變型Z-AAT降低84%

Tempus與Blood Cancer United®攜手打造全球最大規模兒童急性髓系白血病真實世界數據登記庫

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK4611/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4611","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","market":"US","secType":"PLATE","nameCN":"AI醫療","latestPrice":544.34015,"timestamp":1774555199999,"preClose":546.1964,"halted":0,"volume":18192383,"delay":0,"changeRate":-0.003399,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":-1.856262,"latestTime":"03-26 16:00:00 EDT","open":544.6002,"high":563.3901,"low":537.2845,"amount":384507072.75238,"amplitude":0.047795,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1774569600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.604715,"peRate":-11.112089,"turnoverRate":0.026095,"increases":2,"decrements":2,"flats":0,"marketCap":16722360960,"floatMarketCap":12366164608},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","high":563.3901,"amplitude":0.047795,"preClose":546.1964,"low":537.2845,"pbRate":"3.604715","latestPrice":544.34015,"volume":18192383,"delay":0,"open":544.6002,"prevYearClose":658.3995,"prevWeekClose":551.4428,"prevMonthClose":657.8877,"prevQuarterClose":658.3995,"fiveDayClose":566.4931,"twentyDayClose":677.627,"sixtyDayClose":676.0095,"secType":"PLATE","market":"US","turnoverRate":0.026095,"peRate":-11.112089,"marketCap":16722360960,"floatMarketCap":12366164608,"timestamp":1774555199999,"nameCN":"AI醫療"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4611\",,,,undefined,":{"bkCode":"BK4611","up":2,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4611\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1100819924","title":"Tempus與第一三共達成戰略合作 推進AI驅動的生物標誌物發現與ADC臨床項目差異化","url":"https://stock-news.laohu8.com/highlight/detail?id=1100819924","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100819924?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 21:13","pubTimestamp":1774444409,"startTime":"0","endTime":"0","summary":"Tempus AI与第一三共株式会社宣布达成战略合作，旨在利用人工智能技术推进抗体偶联药物（ADC）临床项目中的生物标志物发现与临床差异化研究。根据合作协议，第一三共将采用Tempus自主研发的基础模型及AI技术专长，其中包括PRISM2多模态基础模型，以加速肿瘤治疗领域的创新突破。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEMT","BK4611","BK4121","LU1861559042.SGD","TEM","LU1861558580.USD","DSNKY","BK4613"],"gpt_icon":0},{"id":"2622076512","title":"BUZZ-與第一三共合作開發抗癌藥物，Tempus AI 股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2622076512","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622076512?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 20:49","pubTimestamp":1774442953,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4T40D16A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","BK4611","TEMT","BK4613","TEM","BK4121","LU1861559042.SGD"],"gpt_icon":1},{"id":"1164927646","title":"Recursion Pharmaceuticals任命Vicki Goodman為首席醫療官，2026年4月6日生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1164927646","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164927646?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 20:00","pubTimestamp":1774440051,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals, Inc. 宣布一项重要人事任命：Vicki Goodman将于2026年4月6日正式加入公司，担任首席医疗官一职。此次任命标志着公司在临床开发与医疗战略方面的进一步强化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4611","RXRX","BK4139","BK4548","BK4609"],"gpt_icon":0},{"id":"2622798020","title":"BUZZ-基因編輯藥物有望治療罕見肺病和肝病，Beam Therapeutics公司股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2622798020","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622798020?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 19:28","pubTimestamp":1774438089,"startTime":"0","endTime":"0","summary":"BUZZ-基因编辑药物有望治疗罕见肺病和肝病，Beam Therapeutics公司股价上涨3月25日 - ** 生物技术公司Beam Therapeutics BEAM.O股价盘前上涨12%至27.01美元** 该公司称其实验性基因编辑药物BEAM-302在一项针对α-1抗胰蛋白酶缺乏症的早期研究中取得了令人鼓舞的结果，α-1抗胰蛋白酶缺乏症是一种可损害肺部和肝脏的罕见遗传性疾病。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4T40D11C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","LU1861559042.SGD","BK4585","BK4588","BK4556","BK4505","LU1861558580.USD","BK4139","BK4535","BEAM"],"gpt_icon":0},{"id":"1116095845","title":"Beam Therapeutics股價盤前飆升14%，基因編輯藥物在罕見肺肝疾病試驗中展現積極成果","url":"https://stock-news.laohu8.com/highlight/detail?id=1116095845","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116095845?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 19:19","pubTimestamp":1774437552,"startTime":"0","endTime":"0","summary":"Beam Therapeutics, Inc. (BEAM) 股价在盘前交易中大幅上涨14%，此前该公司宣布其研发的基因编辑药物在一项针对罕见肺肝疾病的临床试验中取得了令人鼓舞的结果。\n这一积极进展显著提振了投资者信心，推动公司股价在开盘前出现强劲上扬。试验数据的披露为Beam Therapeutics在基因治疗领域的技术实力提供了有力证明，同时也为相关罕见疾病患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4556","BK4139","BK4611","BK4505","LU1861559042.SGD","BK4585","LU1861558580.USD","BK4588","BEAM"],"gpt_icon":0},{"id":"1118560812","title":"Beam Therapeutics公司：60毫克劑量被確定為最佳生物劑量，單劑量隊列展現優異安全性與療效","url":"https://stock-news.laohu8.com/highlight/detail?id=1118560812","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118560812?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 19:04","pubTimestamp":1774436652,"startTime":"0","endTime":"0","summary":"Beam Therapeutics公司宣布，基于单剂量队列中展现出的卓越安全性及疗效数据，60毫克剂量已被选定为最佳生物剂量。这一决定凸显了该剂量在治疗窗口中的优势地位，为后续临床开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1861559042.SGD","LU1861558580.USD","BK4611","BK4139","BK4556","BK4505","BK4585","BK4535","BEAM"],"gpt_icon":0},{"id":"1125593240","title":"Beam Therapeutics公布BEAM-302治療α-1抗胰蛋白酶缺乏症1/2期試驗最新積極數據 支持推進關鍵性開發階段","url":"https://stock-news.laohu8.com/highlight/detail?id=1125593240","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125593240?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 19:03","pubTimestamp":1774436620,"startTime":"0","endTime":"0","summary":"Beam Therapeutics近日公布了其在研疗法BEAM-302针对α-1抗胰蛋白酶缺乏症（AATD）的1/2期临床试验最新数据。这些积极结果有力支持该疗法向关键性临床开发阶段推进。试验数据显示，BEAM-302在安全性和有效性方面均表现出令人鼓舞的潜力，为后续研发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4588","LU1861559042.SGD","LU1861558580.USD","BK4611","BK4535","BEAM","BK4585","BK4556","BK4139"],"gpt_icon":0},{"id":"1172694466","title":"Beam Therapeutics：經BEAM-302 60毫克治療後，校正型M-AAT佔總AAT的94%，同時突變型Z-AAT降低84%","url":"https://stock-news.laohu8.com/highlight/detail?id=1172694466","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172694466?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 19:03","pubTimestamp":1774436593,"startTime":"0","endTime":"0","summary":"在Beam Therapeutics公司BEAM-302 60毫克治疗方案下，研究数据显示校正型M-AAT占全部AAT的比例高达94%。与此同时，突变型Z-AAT水平出现显著下降，降幅达到84%。这一结果凸显了该疗法在精准编辑方面的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","BK4585","LU1861558580.USD","BEAM","BK4588","BK4535","LU1861559042.SGD","BK4556","BK4139","BK4505"],"gpt_icon":0},{"id":"1147588835","title":"Tempus與Blood Cancer United®攜手打造全球最大規模兒童急性髓系白血病真實世界數據登記庫","url":"https://stock-news.laohu8.com/highlight/detail?id=1147588835","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147588835?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 20:31","pubTimestamp":1773750710,"startTime":"0","endTime":"0","summary":"Tempus AI与血液癌联合组织Blood Cancer United今日宣布达成战略合作，双方将共同构建全球规模领先的儿童急性髓系白血病真实世界数据登记库。这一创新性数据平台旨在整合多中心临床诊疗信息，通过人工智能技术深度挖掘真实世界证据，为儿科血液肿瘤的精准治疗与药物研发提供关键数据支撑。Tempus AI领先的AI技术与Blood Cancer United的临床网络资源相结合，将加速儿童急性髓系白血病治疗方案的优化，推动个性化医疗发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEMT","LU1861559042.SGD","BK4121","LU1861558580.USD","TEM","BK4611","BK4613"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}]}}